Aberrant calcium channel splicing drives defects in cortical differentiation in Timothy Syndrome
Abstract
The syndromic autism spectrum disorder (ASD) Timothy Syndrome (TS) is caused by a point mutation in the alternatively spliced exon 8A of the calcium channel Cav1.2. Using mouse brain and human induced pluripotent stem cells (iPSCs), we provide evidence that the TS mutation prevents a normal developmental switch in Cav1.2 exon utilization, resulting in persistent expression of gain-of-function mutant channels during neuronal differentiation. In iPSC models, the TS mutation reduces the abundance of SATB2-expressing cortical projection neurons, leading to excess CTIP2+ neurons. We show that expression of TS-Cav1.2 channels in the embryonic mouse cortex recapitulates these differentiation defects in a calcium-dependent manner and that in utero Cav1.2 gain-and-loss of function reciprocally regulates the abundance of these neuronal populations. Our findings support the idea that disruption of developmentally-regulated calcium channel splicing patterns instructively alters differentiation in the developing cortex, providing important in vivo insights into the pathophysiology of a syndromic ASD.
Data availability
All data analyzed in this study have been included in the manuscript and supporting files and figures. Source data files have been provided for Figures 1 to 4, as well as Figure 1-figure supplement 1
Article and author information
Author details
Funding
National Institutes of Health (F31 MH090648 Predoctoral Fellowship)
- Georgia Panagiotakos
National Institutes of Health (R01 MH096815)
- Theo D Palmer
National Institutes of Health (Pioneer Award 5DP1OD3889)
- Ricardo E Dolmetsch
Stanford University School of Medicine (Frances B Nelson Neuroscience Graduate Fellowship)
- Georgia Panagiotakos
University of California, San Francisco (Program for Breakthrough Biomedical Research Sandler Foundation)
- Georgia Panagiotakos
Howard Hughes Medical Institute (International Student Research Award)
- Anshul Rana
Stanford University School of Medicine (Lucile P Markey Graduate Fellowship)
- Anshul Rana
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Postdoctoral Fellowship PBSKP3-123434)
- Thomas Portmann
Brain and Behavior Research Foundation (NARSAD Young Investigator Award)
- Sergiu P Paşca
Simons Foundation (SFARI 206574)
- Theo D Palmer
Blume Foundation
- Theo D Palmer
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal experiments performed in this study were done so in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals and protocols approved by the Stanford University and University of California, San Francisco (UCSF) Institutional Animal Care and Use Committees (Stanford protocol #13705 granted to the lab of Dr. Ricardo Dolmetsch, and UCSF protocol #AN109792 granted to the lab of Dr. Georgia Panagiotakos).
Human subjects: Collection of dermal fibroblasts from TS patients and unaffected control subjects, as well as iPSC generation was previously described (Pasca, et al. 2011). Experiments involving primary dermal fibroblasts and iPSCs from Timothy Syndrome patients and healthy control subjects were conducted at Stanford University under study protocols (#12481, #232, and #327) approved by the Institutional Review Board and Stem Cell Research Oversight (SCRO) committees of Stanford University after obtaining informed consent.
Copyright
© 2019, Panagiotakos et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,337
- views
-
- 531
- downloads
-
- 43
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Neuroscience
Motivation depends on dopamine, but might be modulated by acetylcholine which influences dopamine release in the striatum, and amplifies motivation in animal studies. A corresponding effect in humans would be important clinically, since anticholinergic drugs are frequently used in Parkinson’s disease, a condition that can also disrupt motivation. Reward and dopamine make us more ready to respond, as indexed by reaction times (RT), and move faster, sometimes termed vigour. These effects may be controlled by preparatory processes that can be tracked using electroencephalography (EEG). We measured vigour in a placebo-controlled, double-blinded study of trihexyphenidyl (THP), a muscarinic antagonist, with an incentivised eye movement task and EEG. Participants responded faster and with greater vigour when incentives were high, but THP blunted these motivational effects, suggesting that muscarinic receptors facilitate invigoration by reward. Preparatory EEG build-up (contingent negative variation [CNV]) was strengthened by high incentives and by muscarinic blockade, although THP reduced the incentive effect. The amplitude of preparatory activity predicted both vigour and RT, although over distinct scalp regions; frontal activity predicted vigour, whereas a larger, earlier, central component predicted RT. The incentivisation of RT was partly mediated by the CNV, though vigour was not. Moreover, the CNV mediated the drug’s effect on dampening incentives, suggesting that muscarinic receptors underlie the motivational influence on this preparatory activity. Taken together, these findings show that a muscarinic blocker impairs motivated action in healthy people, and that medial frontal preparatory neural activity mediates this for RT.
-
- Neuroscience
Gamma oscillations in brain activity (30–150 Hz) have been studied for over 80 years. Although in the past three decades significant progress has been made to try to understand their functional role, a definitive answer regarding their causal implication in perception, cognition, and behavior still lies ahead of us. Here, we first review the basic neural mechanisms that give rise to gamma oscillations and then focus on two main pillars of exploration. The first pillar examines the major theories regarding their functional role in information processing in the brain, also highlighting critical viewpoints. The second pillar reviews a novel research direction that proposes a therapeutic role for gamma oscillations, namely the gamma entrainment using sensory stimulation (GENUS). We extensively discuss both the positive findings and the issues regarding reproducibility of GENUS. Going beyond the functional and therapeutic role of gamma, we propose a third pillar of exploration, where gamma, generated endogenously by cortical circuits, is essential for maintenance of healthy circuit function. We propose that four classes of interneurons, namely those expressing parvalbumin (PV), vasointestinal peptide (VIP), somatostatin (SST), and nitric oxide synthase (NOS) take advantage of endogenous gamma to perform active vasomotor control that maintains homeostasis in the neuronal tissue. According to this hypothesis, which we call GAMER (GAmma MEdiated ciRcuit maintenance), gamma oscillations act as a ‘servicing’ rhythm that enables efficient translation of neural activity into vascular responses that are essential for optimal neurometabolic processes. GAMER is an extension of GENUS, where endogenous rather than entrained gamma plays a fundamental role. Finally, we propose several critical experiments to test the GAMER hypothesis.